by YUTA MAEDA – Nikkei –
TOKYO — A Japanese startup is poised to become the first in the world to seek government approval for a therapy derived from human induced pluripotent stem (iPS) cells, Nikkei has learned, with a less invasive alternative for treating heart disease.
Osaka University-affiliated Cuorips has developed a cardiac tissue sheet using iPS cells, which can be grafted onto the hearts of patients suffering from coronary artery disease.
